Windtree Therapeutics Inc【WINT】株式ニュース

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure

WARRINGTON, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India

WARRINGTON, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Windtree Therapeutics, Inc. Announces Reverse Stock Split

WARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree”...

Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference

WARRINGTON, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Form 8-K - Current report

Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline

WARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Form 8-K - Current report

Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline

WARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference

WARRINGTON, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”...

Form 8-K - Current report

glenn1919 3日前

WINT........................................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

WINT, new 52 week low

👍️ 1

getmoreshares 2週前

RS info -1 for 50- feb 20--Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on February 3, 2025. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.
The reverse stock split will become effective on February 20, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) on February 21, 2025 at market open under the existing ticker symbol, “WINT.” The reverse stock split is intended to increase the price per share of the Company’s common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, among other benefits.

👍️0

big bambino 3週前

big uptick on GNS also 😅

WINT.............................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

Jumped in today .125 heavy

👍️0

getmoreshares 4週前

great site- thanks RS 5 to 50 Vote Approved

👍️0

bigbux1 4週前

Scroll 9 down...https://dilutiontracker.com/app/reverse-split

👍️0

getmoreshares 1月前

RS approved- no ratio announced yet

👍️0

BigJuan 1月前

$WINT Hmm reversal here starting? Maybe run before 2/3 meeting.

👍️0

big bambino 1月前

checked for reason on surge and nothing visible, even on website

👍️0

Mr. Zen 3月前

today announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a well-received presentation highlighting the data on istaroxime from the recently completed Phase 2b SEISMiC B study in early cardiogenic shock due to heart failure. The presentation was given at the Cardiovascular Clinical Trials Conference in Washington, DC.

Dr. Alexandre Mebazaa is Professor of Medicine at Université Paris Cité (France), Chair of Department of Anesthesia & Critical Care and an expert in heart failure and cardiogenic shock. He is part of the task force that wrote the 2021 ESC/HFA Guidelines of Heart Failure and the 2023 addendum.

Took another position here, this could very easily be a $30.00 stock in 2 years, patience pays.

👍️ 1

tw0122 4月前

Ping pong .80s to $1s

👍️0

Mr. Zen 4月前

This may be the bottom for a longer term play,if they are successful with phase three it will be a $30.00 +/- stock. IMO

👍 2

glenn1919 4月前

WINT.....................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

👍️0

tw0122 4月前

WINT take smaller gain .94s to $1.20 exit having trouble on bigger breakout to $1.40s

WINT $1.11 breakout solid and $1.44
Up next 3m floater

👍️0

Mr. Zen 5月前

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.

Yup they pr only to dilute there share pos?? Imo

👍️0

Mr. Zen 5月前

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the trial design of its SEISMiC Phase 2b has been published by the European Society of Cardiology Heart Failure. The article is entitled, “Safety and efficacy of up to 60 hours of intravenous istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.” It can be found online in Wiley Online Library DIO: 10.1002/ehf2.15102. Results can be viewed at https://ir.windtreetx.com/corporate-presentation. The Heart Failure Society of America also shared the results.

WINT anew 52 week low

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

On September 25, 2024, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Company’s Phase 2b SEISMiC Extension Study of istaroxime in treating early cardiogenic shock due to heart failure. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

👍️0

glenn1919 6月前

WINT...................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

👍️0

na na 6月前

There's a big borrowing fee. 50 dollars in losses per 1000 dollars of shorted shares per day.

👍️0

tw0122 6月前

FOR RESALE OF UP TO 27.7 MILLION SHARES BY THE SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: Further company coverage:

Wow!!

👍️0

tw0122 6月前

My bad 10 million shares offering announced recently this won’t go anywhere. Share selling machine short it

👍️0

tw0122 6月前

Pop it to $5 already another 400k floater $3.85 resistance watch

If you short 1000 dollars of shares you're now paying 70 dollars a day in fees,Up from 50 dollars of fees a few days ago.

👍️0

na na 6月前

Jumped from 700 percent to 800 percent borrow fee.

👍️0

Anite 6月前

For the upcoming trading day on Friday, 6th we expect Windtree Therapeutics Inc to open at $3.05 and during the day (based on 14 day Average True Range), to move between $3.10 and $4.75, which gives a possible trading interval (+/-54.61%) up from last closing price. If Windtree Therapeutics Inc takes out the full calculated possible swing range there will be an estimated 109.21% move between the lowest and the highest trading price during the day.

👍️0

Anite 6月前

Last week:First, the private placement delivers needed capital to support company operations, including the active Phase 2b clinical trial for istaroxime in cardiogenic shock. Second, the transaction fully converted and eliminated senior notes, including senior secured notes we used as bridge financing over the past several months eliminating this debt from our balance sheet.”
Windtree shares are blasting higher on heavy volume Friday with more than 9 million shares

👍️0

Anite 6月前

Borrow rates now 1500%!!!!!

🚀 1

Mr. Zen 6月前

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability of istaroxime to improve heart function and low blood pressure in the setting of early cardiogenic shock due to heart failure. The Company is looking to extend the positive results on these parameters as observed in the Company’s first SEISMiC Phase 2 clinical study that was previously reported. In addition, the Company hopes that the study results will substantiate the encouraging observations from the Company’s Phase 2 clinical study, indicating istaroxime has a favorable renal profile and does not increase cardiac arrhythmias. The SEISMiC Extension Study is utilizing longer dosing duration and tapering the dosing to assess the potential benefits.

Istaroxime is a novel first-in-class therapy that has demonstrated the ability to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function in patients with compromised cardiac function in three positive Phase 2 trials enrolling patients with acute heart failure (AHF). Cardiogenic shock is a serious condition that can occur when AHF patients continue to deteriorate and the heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. Mortality rates are significant and, depending on severity, range from 7% to 40% in the U.S. There is a lack of satisfactory pharmacological intervention to reverse the condition as available therapies have unwanted side effects such as risk for arrhythmias, decreased blood pressure, and renal dysfunction that limit their usefulness and position them as “rescue medicines” for severe cases. The cardiogenic shock worldwide total market value is estimated to be $1.25 billion per year.

👍️0

na na 6月前

RIP SHORTS! 50 dollars per 1000 dollars of share fee.

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター